1. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. Issue 5 (16th April 2022) Authors: Panayiotidis, Panayiotis; Tumyan, Gayane; Thieblemont, Catherine; Ptushkin, Vadim V.; Marin-Niebla, Ana; García-Sanz, Ramon; Le Gouill, Steven; Stathis, Anastasios; Bottos, Alessia; Hamidi, Habib; Katz, Pablo; Perretti, Thomas; Willis, Jenna C.; Buske, Christian Journal: Leukemia & lymphoma Issue: Volume 63:Issue 5(2022) Page Start: 1058 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗